Compare Novartis AG (NVS) vs iShares TIPS Bond ETF (TIP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs iShares TIPS Bond ETF — how do they compare? Novartis AG trades at $143.2 (market cap $268.57B), while iShares TIPS Bond ETF trades at $104.33 (market cap $14.17B). The key difference: Novartis AG is far larger — about 19× iShares TIPS Bond ETF's market cap, and Novartis AG pays a 3.31% dividend while iShares TIPS Bond ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novartis AG for 82 Days and iShares TIPS Bond ETF for 61 Days on average.
| NVS | TIP | |
|---|---|---|
Market Cap | $268.57B | $14.17B |
Volume | 1,532,573 | 1,780,688 |
Sector | Health | Fixed Income |
52-Week High | $168.62 | $112.20 |
52-Week Low | $121.80 | $103.98 |
Typical Hold Time | 82 Days | 61 Days |
Enterprise Value | $309.89B | — |
Dividend Yield | 3.31% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $143.28, up 1.77% on the day, with a neutral technical signal and mixed earnings history. The company reported strong 2025 revenue of $56.67B and a net income margin of 22.5%, supported by a recent $7.8B licensing deal with China's Abogen. However, recent clinical trial setbacks and an ongoing law firm investigation introduce uncertainty.
The outlook is balanced; solid profitability and a consensus price target of $146.00 suggest modest upside, but risks from pipeline failures and heightened M&A scrutiny warrant caution. Investor sentiment is mixed, with analysts predominantly holding a neutral stance amid evolving business developments.
TIP trades at $104.24 with minimal daily movement (+0.06%). Technical indicators show a bearish bias with moving averages signaling caution while oscillators remain neutral. The ETF faces headwinds from rising bond yields and inflationary pressures affecting fixed income markets. Recent institutional activity shows Envestnet Asset Management increased its stake by 3.5% in the latest quarter.
The outlook remains challenging amid persistent bond market volatility and rising interest rates. Investment opportunity exists for inflation-protected exposure, though risks include continued yield increases and geopolitical tensions driving oil prices higher. Current technical weakness suggests cautious positioning may be warranted until market conditions stabilize.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About iShares TIPS Bond ETF
TIP is the flagship ETF for U.S. Treasury Inflation-Protected Securities (TIPS). It tracks an index of government bonds whose principal value adjusts based on the Consumer Price Index (CPI), providing a direct hedge against rising inflation.
Read more on TIP →
